# APGE (Apogee Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Apogee Therapeutics, Inc. reported $1.34B in total assets and a net loss of $294.4M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/APGE
- Markdown: https://convexityos.com/fundamentals/APGE.md
- SEC CIK: 0001974640
- Reporting currency: USD
- Latest filing period: June 30, 2026
- Last synced: Nov 20, 2026, 05:11 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001974640&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$328.1M | Operating profit |
| Net Income | FY 2025 | -$294.4M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$3.90 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$232.6M | Operating CF less CapEx |
| Cash & ST Investments | Jun 30, 2026 | $971.9M | Total debt: $6.83M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Research & Development | $214.7M | $167.9M | $68.42M | $27.79M |
| Total Operating Expenses | $285.6M | $216.9M | $93.00M | $30.73M |
| **Operating Income** | -$285.6M | -$216.9M | -$93.00M | -$30.73M |
| **EBITDA** | -$284.2M | -$216.7M | -- | -- |
| Interest Income | $30.03M | $34.74M | $9.02M | $92K |
| Income Before Tax | -$255.6M | -$182.1M | -$83.98M | -- |
| Income Tax Expense | $278K | $18K | $0 | -- |
| **Net Income** | -$255.8M | -$182.1M | -$83.98M | -$39.78M |
| Basic EPS | -$4.22 | -$3.30 | -$3.36 | -$16.16 |
| **Diluted EPS** | -$4.22 | -$3.30 | -$3.36 | -$16.16 |
| Basic Shares Outstanding | 60.7M | 55.2M | 25.0M | 2.5M |
| Diluted Shares Outstanding | 60.7M | 55.2M | 25.0M | 2.5M |

### Income Statement (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $67.30M | $60.82M | $58.44M | $54.18M | $55.70M | $46.39M | $60.23M | $45.71M |
| Total Operating Expenses | $96.00M | $82.77M | $78.06M | $71.28M | $73.17M | $63.10M | $75.88M | $58.69M |
| **Operating Income** | -$96.00M | -$82.77M | -$78.06M | -$71.28M | -$73.17M | -$63.10M | -$75.88M | -$58.69M |
| **EBITDA** | -$95.60M | -$82.36M | -$77.65M | -$70.88M | -$72.77M | -$62.89M | -$75.81M | -$58.64M |
| Interest Income | $11.81M | $8.74M | $8.73M | $6.32M | $7.14M | $7.84M | $8.68M | $9.67M |
| Interest Expense | $1.58M | -- | -- | -- | -- | -- | -- | -- |
| Income Before Tax | -$85.78M | -$74.03M | -$69.33M | -$64.96M | -$66.02M | -$55.26M | -$67.20M | -$49.02M |
| Income Tax Expense | $78K | $79K | $62K | $61K | $72K | $83K | $18K | $0 |
| **Net Income** | -$85.85M | -$74.11M | -$69.39M | -$65.02M | -$66.10M | -$55.34M | -$67.22M | -$49.02M |
| Basic EPS | -$1.14 | -$1.06 | -- | -$1.11 | -$1.13 | -$0.95 | -- | -$0.86 |
| **Diluted EPS** | -$1.14 | -$1.06 | -- | -$1.11 | -$1.13 | -$0.95 | -- | -$0.86 |
| Basic Shares Outstanding | 75.4M | 69.7M | -- | 58.8M | 58.4M | 58.2M | -- | 56.8M |
| Diluted Shares Outstanding | 75.4M | 69.7M | -- | 58.8M | 58.4M | 58.2M | -- | 56.8M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $131.5M | $141.8M | $118.3M | $151.9M |
| Short-Term Investments | $598.6M | $378.9M | $277.1M | -- |
| **Cash & Short-Term Investments** | $730.2M | $520.7M | $395.5M | $151.9M |
| Other Current Assets | $605K | $1.74M | $1.21M | $57K |
| **Total Current Assets** | $741.4M | $529.7M | $398.4M | $152.1M |
| Property, Plant & Equipment, Net | $5.69M | $1.96M | $377K | -- |
| Long-Term Investments | $172.7M | $210.4M | -- | -- |
| Other Non-Current Assets | $8.67M | $498K | $401K | -- |
| **Total Non-Current Assets** | $195.8M | $224.2M | $3.00M | $0 |
| **Total Assets** | $937.1M | $754.0M | $401.4M | $152.1M |
| Accounts Payable | $1.22M | $1.07M | $2.14M | $418K |
| **Total Current Liabilities** | $27.91M | $28.56M | $20.56M | $9.98M |
| **Total Non-Current Liabilities** | $5.34M | $8.60M | $933K | $0 |
| **Total Liabilities** | $33.25M | $37.16M | $21.49M | $9.98M |
| **Total Debt (incl. Leases)** | $8.85M | $11.83M | $2.00M | -- |
| Common Stock | $1.0K | $1.0K | -- | -- |
| Retained Earnings | -$561.8M | -$305.9M | -$123.8M | -$39.78M |
| Accumulated Other Comp. Income | $1.08M | $915K | $329K | -- |

### Balance Sheet (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $105.6M | $451.8M | $131.5M | $107.9M | $124.2M | $106.9M | $141.8M | $118.8M |
| Short-Term Investments | $866.4M | $608.1M | $598.6M | $419.4M | $381.2M | $406.4M | $378.9M | $407.3M |
| **Cash & Short-Term Investments** | $971.9M | $1.06B | $730.2M | $527.3M | $505.4M | $513.3M | $520.7M | $526.0M |
| Other Current Assets | $1.44M | $1.18M | $605K | $919K | $963K | $586K | $1.74M | $396K |
| **Total Current Assets** | $991.7M | $1.07B | $741.4M | $540.1M | $516.1M | $521.5M | $529.7M | $534.5M |
| Property, Plant & Equipment, Net | $4.82M | $5.28M | $5.69M | $6.03M | $6.44M | $5.68M | $1.96M | $1.42M |
| Long-Term Investments | $321.9M | $198.4M | $172.7M | $61.64M | $115.8M | $168.1M | $210.4M | $227.7M |
| Other Non-Current Assets | $10.61M | $8.52M | $8.67M | $8.74M | $8.86M | $7.34M | $498K | $514K |
| **Total Non-Current Assets** | $344.1M | $219.9M | $195.8M | $86.06M | $141.7M | $192.6M | $224.2M | $241.8M |
| **Total Assets** | $1.34B | $1.29B | $937.1M | $626.2M | $657.8M | $714.2M | $754.0M | $776.3M |
| Accounts Payable | $3.08M | $1.24M | $1.22M | $376K | $5.68M | $2.44M | $1.07M | $2.22M |
| **Total Current Liabilities** | $37.51M | $32.95M | $27.91M | $34.05M | $31.55M | $32.96M | $28.56M | $32.61M |
| **Total Non-Current Liabilities** | $103.7M | $4.91M | $5.34M | $5.77M | $6.82M | $7.84M | $8.60M | $9.27M |
| **Total Liabilities** | $141.2M | $37.86M | $33.25M | $39.82M | $38.37M | $40.80M | $37.16M | $41.88M |
| **Total Debt (incl. Leases)** | $6.83M | $8.05M | $8.85M | $9.85M | $10.85M | $11.82M | $11.83M | $12.14M |
| Common Stock | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K |
| Retained Earnings | -$721.7M | -$635.9M | -$561.8M | -$492.4M | -$427.4M | -$361.3M | -$305.9M | -$238.7M |
| Accumulated Other Comp. Income | -$2.50M | -$749K | $1.08M | $1.03M | $685K | $1.07M | $915K | $3.27M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Net Income | -$255.8M | -$182.1M | -$83.98M | -$39.78M |
| Depreciation & Amortization | $1.42M | $189K | -- | -- |
| Stock-Based Compensation | $46.28M | $23.33M | $6.10M | $2.14M |
| Change in Payables | $150K | -$1.07M | $1.61M | $418K |
| **Operating Cash Flow** | -$227.4M | -$171.2M | -$74.76M | -$16.43M |
| Capital Expenditure | -$5.15M | -$1.15M | -$167K | -- |
| **Free Cash Flow** | -$232.6M | -$172.3M | -$74.93M | -- |
| Purchases of Investments | -$642.3M | -$649.5M | -$303.7M | -- |
| **Investing Cash Flow** | -$179.6M | -$300.5M | -$273.9M | -- |
| Common Stock Issued | -- | $450.0M | $315.4M | -- |
| **Financing Cash Flow** | $396.5M | $495.1M | $315.4M | $168.3M |
| **Net Change in Cash** | -$10.53M | $23.47M | -$33.28M | $151.9M |

### Cash Flow Statement (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$85.85M | -$74.11M | -$69.39M | -$65.02M | -$66.10M | -$55.34M | -$67.22M | -$49.02M |
| Depreciation & Amortization | $400K | $408K | $406K | $400K | $400K | $207K | $76K | $48K |
| Stock-Based Compensation | $16.66M | $17.16M | $11.93M | $11.88M | $11.34M | $11.13M | $7.61M | $5.84M |
| Change in Payables | $1.84M | $16K | $845K | -$5.30M | $3.23M | $1.37M | -$1.15M | -$3.31M |
| **Operating Cash Flow** | -$71.38M | -$55.57M | -$62.69M | -$54.26M | -$62.03M | -$48.48M | -$67.71M | -$42.52M |
| Capital Expenditure | -- | -- | -$62K | $0 | -$768K | -$4.32M | $1.0K | -$751K |
| **Free Cash Flow** | -- | -- | -$62.75M | -$54.26M | -$62.80M | -$52.79M | -$67.71M | -$43.27M |
| Purchases of Investments | -$552.8M | -$183.2M | -$389.1M | -$107.6M | -$47.38M | -$98.20M | -$60.58M | -$236.0M |
| **Investing Cash Flow** | -$381.9M | -$35.35M | -$288.6M | $17.95M | $78.12M | $12.98M | $46.37M | -$146.4M |
| Common Stock Issued | -$728K | $378.2M | -- | $0 | $0 | $0 | $0 | $0 |
| **Financing Cash Flow** | $107.0M | $411.2M | $374.9M | $19.74M | $1.18M | $622K | $44.36M | $383K |
| **Net Change in Cash** | -$346.2M | $320.2M | $23.64M | -$16.57M | $17.28M | -$34.87M | $23.01M | -$188.5M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Return on Assets (ROA) | -27.3% | -24.2% | -20.9% | -26.2% |
| Current Ratio | 26.57x | 18.55x | 19.38x | 15.24x |
| Quick Ratio | 26.17x | 18.23x | 19.24x | 15.22x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Assets (ROA) | -22.0% | -21.2% | -27.3% | -40.5% | -36.1% | -28.8% | -24.2% | -18.9% |
| Current Ratio | 26.44x | 32.59x | 26.57x | 15.86x | 16.36x | 15.82x | 18.55x | 16.39x |
| Quick Ratio | 25.91x | 32.16x | 26.17x | 15.49x | 16.02x | 15.57x | 18.23x | 16.13x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
